Literature DB >> 35800099

Measurement of Cell Intrinsic TGF-β Activation Mediated by the Integrin αvβ8.

Robert Ian Seed1, Stephen Lloyd Nishimura1,2.   

Abstract

Transforming growth factor beta (TGF-β) is a multi-functional cytokine that plays a significant role in multiple diseases, including fibrosis and tumor progression. Whilst the biologic effects of TGF-β are well characterized, it is unclear how TGF-β signaling is regulated to impart specific responses within certain cell types. One mechanism of regulation may be through TGF-β activation, since TGF-β is always expressed in a latent form (L-TGF-β). Campbell et al.(2020) recently presented a new structural model to demonstrate how the integrin αvβ8 might specifically control TGF-β activation and signaling. In this model, αvβ8 binds to cell surface L-TGF-β1 to induce a conformational change, which exposes mature TGF-β peptide to TGF-β receptors (TGF-βRs), allowing initiation of TGF-β signaling from within the latent complex. This model also predicts that TGF-β signaling would be directed specifically towards the TGF-β expressing cell surface. We sought to test the validity of the new structural model by creating a cell-based assay which utilizes luciferase TGF-β reporter cells (TMLC). TMLC cells express high levels of TGF-βRs, but do not express cell surface L-TGF-β. We modified TMLC reporter cells to express cell surface L-TGF-β1 in a mutant form, which prevents the release of mature TGF-β from the latent complex. The newly generated cell lines were then used in a novel functional assay to investigate whether integrin αvβ8 could potentiate cell intrinsic TGF-β signaling from within the latent complex in vitro.
Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Integrin; Reporter assay; TGF-β

Year:  2022        PMID: 35800099      PMCID: PMC9081475          DOI: 10.21769/BioProtoc.4385

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  8 in total

Review 1.  TGF-beta: from latent to active.

Authors:  N Khalil
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

2.  Targeting TGFβ Signalling in Cancer: Toward Context-Specific Strategies.

Authors:  Rhiannon French; Yuliang Feng; Siim Pauklin
Journal:  Trends Cancer       Date:  2020-04-08

3.  An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct.

Authors:  M Abe; J G Harpel; C N Metz; I Nunes; D J Loskutoff; D B Rifkin
Journal:  Anal Biochem       Date:  1994-02-01       Impact factor: 3.365

4.  Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1.

Authors:  J S Munger; J G Harpel; F G Giancotti; D B Rifkin
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

5.  A tumor-specific mechanism of Treg enrichment mediated by the integrin αvβ8.

Authors:  Robert I Seed; Kenji Kobayashi; Saburo Ito; Naoki Takasaka; Anthony Cormier; Jillian M Jespersen; Jean Publicover; Suprita Trilok; Alexis J Combes; Nayvin W Chew; Jocelyne Chapman; Matthew F Krummel; Jianlong Lou; James Marks; Yifan Cheng; Jody L Baron; Stephen L Nishimura
Journal:  Sci Immunol       Date:  2021-03-26

6.  The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1.

Authors:  Dezhi Mu; Stephanie Cambier; Lars Fjellbirkeland; Jody L Baron; John S Munger; Hisaaki Kawakatsu; Dean Sheppard; V Courtney Broaddus; Stephen L Nishimura
Journal:  J Cell Biol       Date:  2002-04-22       Impact factor: 10.539

Review 7.  TGF-β - an excellent servant but a bad master.

Authors:  Lenka Kubiczkova; Lenka Sedlarikova; Roman Hajek; Sabina Sevcikova
Journal:  J Transl Med       Date:  2012-09-03       Impact factor: 5.531

Review 8.  Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling.

Authors:  Warisara Parichatikanond; Theerut Luangmonkong; Supachoke Mangmool; Hitoshi Kurose
Journal:  Front Cardiovasc Med       Date:  2020-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.